Neurodegenerative Disease Treatment Drug PBT2 Breaks Intrinsic Polymyxin Resistance in Gram-Positive Bacteria
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neurodegenerative Disease Treatment Drug PBT2 Breaks Intrinsic Polymyxin Resistance in Gram-Positive Bacteria
Authors
Keywords
-
Journal
Antibiotics-Basel
Volume 11, Issue 4, Pages 449
Publisher
MDPI AG
Online
2022-03-26
DOI
10.3390/antibiotics11040449
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rescuing Tetracycline Class Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii Pulmonary Infection
- (2022) David M. P. De Oliveira et al. mBio
- Dysregulation of Streptococcus pneumoniae zinc homeostasis breaks ampicillin resistance in a pneumonia infection model
- (2022) Erin B. Brazel et al. Cell Reports
- Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane
- (2021) Akshay Sabnis et al. eLife
- Antimicrobial Resistance in ESKAPE Pathogens
- (2020) David M. P. De Oliveira et al. CLINICAL MICROBIOLOGY REVIEWS
- Multiple Bactericidal Mechanisms of the Zinc Ionophore PBT2
- (2020) Nichaela Harbison-Price et al. mSphere
- Repurposing a neurodegenerative disease drug to treat Gram-negative antibiotic-resistant bacterial sepsis
- (2020) David M. P. De Oliveira et al. Science Translational Medicine
- Group A Streptococcus coordinates manganese import and iron efflux in response to hydrogen peroxide stress
- (2019) Andrew G Turner et al. BIOCHEMICAL JOURNAL
- Atlas of group A streptococcal vaccine candidates compiled using large-scale comparative genomics
- (2019) Mark R. Davies et al. NATURE GENETICS
- Chemical Synergy between Ionophore PBT2 and Zinc Reverses Antibiotic Resistance
- (2018) Lisa Bohlmann et al. mBio
- Perturbation of manganese metabolism disrupts cell division inStreptococcus pneumoniae
- (2017) Julia E. Martin et al. MOLECULAR MICROBIOLOGY
- Incidence and Outcomes Associated With Infections Caused by Vancomycin-Resistant Enterococci in the United States: Systematic Literature Review and Meta-Analysis
- (2016) Hsiu-Yin Chiang et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Polymyxin: Alternative Mechanisms of Action and Resistance
- (2016) Michael J. Trimble et al. Cold Spring Harbor Perspectives in Medicine
- Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial
- (2015) LANCET NEUROLOGY
- Manganese Homeostasis in Group A Streptococcus Is Critical for Resistance to Oxidative Stress and Virulence
- (2015) Andrew G. Turner et al. mBio
- Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management
- (2015) Christopher Crank et al. Infection and Drug Resistance
- Disease Manifestations and Pathogenic Mechanisms of Group A Streptococcus
- (2014) M. J. Walker et al. CLINICAL MICROBIOLOGY REVIEWS
- An Antimicrobial Role for Zinc in Innate Immune Defense Against Group A Streptococcus
- (2014) Cheryl-lynn Y. Ong et al. JOURNAL OF INFECTIOUS DISEASES
- A Systematic and Functional Classification of Streptococcus pyogenes That Serves as a New Tool for Molecular Typing and Vaccine Development
- (2014) Martina Sanderson-Smith et al. JOURNAL OF INFECTIOUS DISEASES
- Staphylococcus aureus bloodstream infection: A pooled analysis of five prospective, observational studies
- (2013) Achim J. Kaasch et al. JOURNAL OF INFECTION
- Emergence of Epidemic Multidrug-Resistant Enterococcus faecium from Animal and Commensal Strains
- (2013) F. Lebreton et al. mBio
- Peroxide Stimulon and Role of PerR in Group A Streptococcus
- (2011) R. Grifantini et al. JOURNAL OF BACTERIOLOGY
- Iron enzyme ribulose-5-phosphate 3-epimerase in Escherichia coli is rapidly damaged by hydrogen peroxide but can be protected by manganese
- (2011) J. M. Sobota et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial
- (2008) Lars Lannfelt et al. LANCET NEUROLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started